| 发明名称 | Methods and antibodies for treating cancer | ||
| 摘要 | The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR,said second antibody binds EGFR,said first and second antibody are non-cross-blocking, andthe dosage regimen is such that CDC is obtained at the tumor site. | ||
| 申请公布号 | US9540450(B2) | 申请公布日期 | 2017.01.10 |
| 申请号 | US201414199391 | 申请日期 | 2014.03.06 |
| 申请人 | GENMAB A/S | 发明人 | Van De Winkel Jan;Parren Paul;Bleeker Willem Karel;Edvardsen Klaus;Van Bueren Jeroen Lammerts;Valerius Thomas;Dechant Michael;Weisner Wencke;Berger Sven |
| 分类号 | C07K16/28;C07K16/40;C07K16/44;C07K16/46;G01N33/573;A61K39/00 | 主分类号 | C07K16/28 |
| 代理机构 | Nelson Mullins Riley & Scarborough LLP | 代理人 | Nelson Mullins Riley & Scarborough LLP ;Remillard, Esq. Jane E.;Frank Christopher L. |
| 主权项 | 1. An isolated monoclonal antibody, or an antigen binding portion thereof, which binds to EGFR and comprising the CDR1, CDR2, and CDR3 sequences of the heavy and light chain variable region sequences set forth in SEQ ID NOs: 17 and 18, respectively. | ||
| 地址 | Copenhagen DK | ||